Upon ligand binding, FGFRs activate the RAS/MAPK/ERK, PI3K/AKT, and JAK/STAT pathways and contribute to cancer cells’ survival, proliferation, and angiogenic signaling [141]. This evidence concerns the gene AKT1 and cancer.